CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Inclusion Criteria: * 1\. Male or female * 2\. Aged 2 to 11 years, inclusive, with body weight ? 10th percentile based on age * 3\. Diagnosed with clinically confirmed C1-INH HAE * 4\. Experienced ? 2 HAE attacks during the 6 months before Screening Exclusion Criteria: * 1\. Concomitant diagnosis of another form of angioedema, such as idiopathic or acquired angioedema, recurrent angioedema associated with urticaria, or HAE type 3 * 2\. Use of C1-INH products, androgens, antifibrinolytics, approved or future approved medications, or other small molecule medications for routine prophylaxis against HAE attacks within a minimum of 2 weeks before the Treatment Period * 3\. Participation in another interventional clinical study during the 30 days before the Treatment Period or within 5 half-lives of the final dose of the investigational product administered during the previous interventional study, whichever is longer * 4\. Having laboratory clinical abnormalities assessed as clinically significant by the investigator in results of hematology or chemistry assessments performed during Screening * 5\. Currently receiving a therapy not permitted during the study * 6\. Being pregnant or breastfeeding.